KLOW Peptide: The Complete Guide

What Is the KLOW Peptide Blend?

KLOW is not a single molecule. It is a name for four peptides compounded together in one vial: BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , KPV, and TB-500. Each has its own research history, its own mechanism, and its own reputation. The blend exists because the four cover different stages of tissue repair, and people recovering from injuries were already stacking them separately before pharmacies started combining them.

The name itself is an evolution. The older three-peptide combination of GHK-Cu, BPC-157, and TB-500 circulates under the name GLOW. Add KPV, an anti-inflammatory tripeptide, and you get KLOW. If you are weighing the two against each other, or against the plain BPC-157/TB-500 pair that people call the Wolverine stack, our GLOW vs KLOW vs Wolverine comparison Read nextGLOW vs KLOW vs Wolverine Stack: Which One?Three nicknames, four peptides, one recurring confusion. GLOW is GHK-Cu plus BPC-157 plus TB-500. KLOW is GLOW with KPV added. The Wolverine stack is BPC-157 and TB-500 on their own. Here is what each name actually contains, which goal each one fits, what a prescribing clinic dispenses in their place, and why an $80 research vial and a $349 pharmacy vial are not the same product.Read article breaks down all three head to head.

Because KLOW is a name rather than a standardized drug, what is actually in the vial depends entirely on who made it. The version prescribed through PeRx is compounded by a US 503A pharmacy at 3 mg BPC-157, 10 mg GHK-Cu, 3 mg KPV, and 3 mg TB-500 per mL, in a 5 mL vial. That is 95 mg of total peptide, with GHK-Cu making up more than half by weight. The vial ships fully reconstituted and ready to use, refrigerated, with insulin syringes and alcohol swabs in the box. There is no powder and no mixing step.

Why Four Peptides in One Vial?

Tissue repair is not one process. An injury needs blood supply restored, new structural protein laid down, cells physically migrating to the damage, and an inflammatory response that helps rather than lingers. No single peptide covers all of that. The logic of KLOW is to assign each job to the component with the strongest case for it.

BPC-157: the local repair signal

BPC-157 is a 15-amino-acid peptide derived from a protein in human gastric juice, and it anchors nearly every recovery blend for a reason. In animal studies it promotes angiogenesis, the growth of new blood vessels, through the VEGF pathway, and it upregulates growth factor receptors at the injury site. That matters most for tendons and ligaments, which heal slowly precisely because their blood supply is poor. It is the most studied peptide in the vial, with a literature spanning three decades. Our complete BPC-157 guide Read nextBPC-157: Complete Guide to Body Protection CompoundA peptide discovered in a Croatian lab in the early '90s is now one of the most studied healing compounds in regenerative medicine. Here's what the science actually says, where it came from, and what you should know before starting.Read article covers it in depth.

Hsieh MJ et al., "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation," Journal of Molecular Medicine, 2017. Cell and rodent models. View study

GHK-Cu: collagen and connective tissue

GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma and declines with age. It has been studied since the 1970s, mostly in wound healing and skin, where it signals for collagen and elastin synthesis and tissue remodeling. A 2018 review by Pickart, the researcher who discovered it, catalogs its effects on gene expression related to tissue repair. It is the highest-concentration component of KLOW, and the one responsible for the skin and connective-tissue angle that the other three do not cover.

Pickart L, Margolina A, "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data," International Journal of Molecular Sciences, 2018. View study

KPV: the inflammatory brake

KPV is the smallest component, a three-amino-acid fragment (lysine-proline-valine) of the hormone alpha-MSH. The fragment keeps the parent molecule's anti-inflammatory activity while dropping its pigmentation effects. The best-known study on it showed KPV entering intestinal cells through the PepT1 transporter and reducing inflammatory signaling in cell culture and in mice. It is the ingredient that turns GLOW into KLOW, and the one most people have never heard of. What Is KPV? Read nextWhat Is KPV? The Peptide Inside KLOWKPV is three amino acids long, which makes it one of the smallest molecules anyone calls a peptide. It came out of hormone research in the late 1980s, it has a real literature behind it, and almost none of that literature involves humans. Here is what is actually known, why PeRx only supplies it inside a four-peptide blend, and what the July 2026 FDA panel vote did and did not do.Read article tells its full story, including the July 2026 FDA advisory committee vote on it.

Dalmasso G et al., "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation," Gastroenterology, 2008. Cell culture and mouse models. View study

TB-500: systemic recovery

TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell migration. Where BPC-157 concentrates its effects near the injection site, thymosin beta-4 works body-wide, upregulating actin so that repair cells can physically move to where they are needed. The wound-healing research behind this mechanism was done on the full thymosin beta-4 molecule, in animal models and in early-phase human trials. The TB-500 fragment itself has essentially no published human data, which is worth knowing and which we come back to below.

Malinda KM et al., "Thymosin beta4 accelerates wound healing," Journal of Investigative Dermatology, 1999. Animal models of the full thymosin beta-4 protein. View study

One practical consequence of the blend format deserves its own sentence: the ratio is fixed. Every dose delivers the four peptides in the same proportion, compounded together at the pharmacy, which is the difference between a protocol and a pile of vials. You give up the ability to titrate components individually, and in exchange you get one injection instead of four and no math.

What Is KLOW Used For?

KLOW is prescribed for recovery. In practice, the people who end up on it fall into a few recognizable groups.

Injury and post-procedure recovery. This is the core use case. A tendon that will not settle, a shoulder rebuilt in surgery, a knee that flares every time training volume climbs. The prescription instructs injecting as close to the injury as practical, because BPC-157's effects are strongest locally, while TB-500 and KPV circulate regardless of where the needle goes.

Several problems at once. People managing one clean injury usually start with BPC-157 alone or the BPC/TB-500 combo Read nextBPC-157 and TB-500: Dosing and TimelineOne peptide sends the repair signals. The other moves the construction crew into position and builds the blood supply to keep them working. BPC-157 and TB-500 were discovered decades apart, on different continents, for completely different reasons. Practitioners started combining them because the science pointed to an obvious fit: they cover non-overlapping phases of the same healing process. This is the most widely used peptide combination in injury recovery.Read article . KLOW tends to be the step up for people juggling multiple nagging areas, where a single targeted peptide feels insufficient and running four separate products is impractical.

Skin and connective tissue alongside recovery. The 2 mg of GHK-Cu in every dose is a meaningful amount of the peptide that dermatology research has focused on for decades. Some patients pick KLOW over the plain recovery pair specifically for this, wanting the collagen and elastin signaling included rather than bolted on. If skin is the only goal, though, standalone GHK-Cu is the more sensible prescription. KLOW makes sense when recovery is the reason and skin support is the bonus.

Gut comfort. Two of the four components, BPC-157 and KPV, have their deepest research roots in the GI tract. BPC-157 was isolated from gastric juice and has extensive animal data on gut lining protection. KPV's flagship study was an intestinal inflammation model. Patients on KLOW for an orthopedic problem sometimes report digestive comfort improving as a side benefit. To be clear about the ceiling here: neither peptide is a treatment for any diagnosed digestive condition, and inflammatory bowel disease on your intake is a flag for provider review, not a reason to order KLOW.

What the KLOW Research Actually Shows

Here is the honest version, stated plainly rather than buried under citations: no clinical trial has ever tested the KLOW blend. Nobody has run the four-peptide combination against a placebo, against its components, or against anything else in humans. Everything anyone claims about KLOW as a whole is inference from single-ingredient studies, and those studies are not equal.

BPC-157 has the largest literature, over 100 published papers across three decades, with consistent healing effects across tendon, ligament, muscle, and gut models. Nearly all of it is rodent work, much of it from a single research group in Zagreb. The human data is thin but not zero: a 2021 study of intra-articular BPC-157 injections for knee pain reported that 87.5% of patients had significant relief lasting six months to a year. Small study, no control group, but it exists.

Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine, 2021. View study

GHK-Cu has decades of human data, but almost all of it involves creams, serums, and wound dressings rather than injections. The tissue-remodeling and collagen-signaling mechanisms are well documented. Injectable human dosing data at the levels KLOW delivers is not something the literature contains.

KPV has zero published human studies by any route. Not few. Zero. The FDA staff review that preceded the July 2026 advisory committee vote searched the major databases and reported finding no data on KPV administered to people. What exists is cell culture and mouse work, and it is genuinely interesting mouse work, but a mouse colitis model is not a human trial.

TB-500 occupies a strange middle ground. The parent protein, thymosin beta-4, went through early-phase human wound-healing trials, including work summarized by Treadwell and colleagues in 2012 showing accelerated dermal healing in preclinical models and in patients. Those results are routinely quoted as evidence for TB-500. They are not the same molecule. The synthetic fragment sold as TB-500 has no published human dosing data of its own.

Treadwell T et al., "The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients," Annals of the New York Academy of Sciences, 2012. View study

KLOW Before and After: What to Expect

Search "KLOW peptide results" and you will find before-and-after photos from research-blend users, which describe a different product at a different ratio, and glowing anecdotes with no baseline. Set those aside. What follows is the realistic arc most patients describe on the prescribed six-week protocol, with the caveat that no trial has measured any of it for the blend itself.

A realistic failure mode is worth naming too. Some people finish a cycle and feel nothing. With no human trial of the blend, nobody can honestly quote a response rate. If a full six-week course changes nothing, the answer is not a bigger dose, it is a conversation about whether this blend fits the problem.

How Do You Take KLOW?

KLOW is a subcutaneous injection: a small insulin syringe, a pinch of skin, just under the surface. Not into muscle, never into a tendon or joint. The vial arrives ready to use with no reconstitution needed, so the routine is draw, inject, refrigerate the vial, done. Most people find the whole process takes under a minute once it is familiar.

Your PeRx provider prescribes the protocol, and the label on your vial is the final word. Two companion guides carry the detail this overview deliberately leaves out: the KLOW dosage guide Read nextKLOW Peptide Dosage: Chart, Frequency, CycleNearly every KLOW dosage chart online describes an 80 mg research vial that someone mixes at their kitchen table. The KLOW a physician actually prescribes is a different product with different math. This is the dosing as written on the PeRx prescription: units on the syringe, days per week, weeks per cycle, and what the gray-market charts get wrong.Read article converts the 20-unit dose into per-peptide milligrams, weekly totals, and vial math, and Where to Inject KLOW Read nextWhere to Inject KLOW: Injury Site and RotationKLOW carries a placement instruction most peptides do not: the dose goes as close to the injury site as possible. Four peptides share one vial, and you still have to rotate. Here is how those two instructions fit together in practice.Read article maps injuries to injection regions and covers rotation. Read both before your first dose.

KLOW Side Effects

The honest framing first: side-effect knowledge about KLOW comes from patient reports and from what is known about the components, not from controlled safety trials, because none exist for the blend. With that said, the commonly reported effects are mild.

Injection site reactions are the most frequent: brief redness, a small welt, or soreness where the needle went in. Rotating sites within the region handles most of it. Brief lightheadedness after a dose is reported often enough that the prescription addresses it directly: inject sitting down for the first week and stay seated a few minutes. A temporary metallic taste shows up occasionally and is not by itself a concern.

The blend also carries real exclusions, and they are stricter than a single-peptide prescription because there are four mechanisms in play. Anyone with active cancer or a recent cancer history should not use KLOW, since several components act on blood vessel growth and cell migration. Anyone with Wilson disease or copper sensitivity should not use it, because every dose contains 2 mg of a copper complex. Active infections, autoimmune conditions, and immunosuppressant medications all need provider review because of KPV's action on inflammatory signaling. Pregnancy and breastfeeding are excluded outright for lack of any data.

Seek immediate care for the signs of a serious reaction: swelling of the face or throat, difficulty breathing, a rapid heartbeat, or lightheadedness that lasts beyond 15 to 20 minutes. For the broader picture of what patients report across peptide therapies and when to call a provider, see our peptide side effects guide Read nextPeptide Side Effects: Normal vs. Red Flag (2026)Most peptide side effects are mild local reactions that resolve in a day. A smaller set of systemic effects depends on the pathway the peptide acts on. And a third category, the one worth paying attention to, points to a problem with the product or the patient that should pause the protocol. Here is how to tell them apart.Read article .

How Much Does KLOW Cost?

Through PeRx, KLOW is $349 for a one-month supply. That covers the provider review of your intake, the compounding by a licensed US 503A pharmacy, sterility and potency requirements, overnight cold-chain shipping, and the syringes and swabs in the box. Your card is saved at checkout and charged only if a provider approves the prescription.

The comparison worth making is not against a research-site powder, which is a different legal category with no verification of what is in the vial. It is against assembling the same four peptides as separate prescriptions, which is what people did before combination vials existed. The math is lopsided.

Note what the right-hand column cannot actually buy: PeRx does not sell TB-500 or KPV as standalone vials at all, so the closest do-it-yourself equivalent is two prescriptions, two injections, more money, and a three-peptide protocol instead of four. The single-vial format is not just convenience pricing. It is the only prescribed route to this specific combination. For how the prescription category differs from research-use products generally, see research peptides vs prescription peptides Read nextResearch Peptides vs Prescription Peptides (2026)An honest comparison for the patient who already uses peptides, what the 'Not for Human Use' label actually means, the real quality differences, and the practical steps to switch from research-chemical sourcing to a prescription supply.Read article .

How to Get KLOW

KLOW is prescription-only, and the process is built around that. You complete an online intake covering your health history, current medications, and what you are trying to recover from. The screening asks specifically about the exclusions above, including cancer history, copper issues, and the inflammatory-condition questions tied to KPV. A licensed provider reviews it, and if KLOW is appropriate, the prescription goes to the compounding pharmacy.

The vial arrives by FedEx overnight in refrigerated packaging with an ice block, ready to use, alongside the supplies and an injection guide. It goes straight into the refrigerator, upright and away from light. Before each dose, look at the solution: it should be clear. Particles, cloudiness, or discoloration mean do not use it. From intake to first injection is typically a matter of days.

KLOW: Common Questions